Acute myeloid leukemia (AML) exhibits great heterogeneity in manifestation, sensitivity to therapy and genetic basis of pathology. Numerous studies have implied that AML arises from the sequential accumulation of mutations at the level of the hematopoietic stem/progenitor cell, resulting in a disturbed balance of proliferation, differentiation and apoptosis of immature myeloid progenitors. 1 To gain more insight into somatic mutations that affect biological pathways in tumorigenesis, a systematic mutation analysis of virtually all annotated human protein-coding genes in eleven breast and eleven Figure 1 Location of nucleotide changes observed in ABCB8 and ABCB10 in 94 AML patients compared with GenBank sequences. The conserved domains (transmembrane and adenosine triphosphate (ATP) binding domains) and segments of low compositional complexity (empty blocks) are depicted in the schematic representation of the two transporters. The upper panels of the two schematic diagrams show the variants identified in our patient cohort; the lower panels show the earlier described SNPs not found in our patient cohort. Newly discovered genetic variants and single nucleotide polymorphisms (SNPs) are indicated by their positions at the cDNA level. The filled and empty circles represent new and known SNPs, respectively. The frequency of each variant in our cohort is indicated by the number of patients who carried that variant. (a) Variants observed in the ABCB8 coding region. Three new variants were also present in healthy controls: c.567 C4T (V158V, n ¼ 1, heterozygous), c.2202 A4C (P703P, n ¼ 5, heterozygous) and c.2222 G4T (G710V, n ¼ 8, one homozygous and seven heterozygous). Two new variants were found in remission samples: c.1076 G4A (R328H, n ¼ 1, homozygous) and c.463 C4G (L124V, n ¼ 2, heterozygous, present in the remission sample of one patient and in the T cells cultured from the other patient's cryopreserved peripheral blood sample). Another two new variants were detected in cultured T cells: c.1572 C4T (G493G, n ¼ 1, heterozygous) and c.223 C4T (R44W, n ¼ 1, heterozygous). The remaining new variant, c.915 G4A (S274S, n ¼ 1, heterozygous), was not determined to be somatic or not due to lack of associated normal material. The nonsynonymous SNPs detected in our patient cohort include: c.496 G4A (V135I, n ¼ 5, heterozygous), c.1003 C4T (R304C, n ¼ 9, seven heterozygous and two homozygous) and c.1717 G4A (V542I, n ¼ 5, heterozygous). The SNP c.1003 C4T had a different frequency (0.123) in our patient cohort compared with that described in GenBank (0.339). One synonymous SNP was found in our panel of patients: c.1077 T4A (R328R, n ¼ 30, 25 heterozygous and five homozygous). Seven SNPs present in the GenBank database were not present in our patients. (b) Variants identified in ABCB10. The new variant, c.923 C4T (L254T, n ¼ 1, heterozygous), located in the transmembrane domain was present in the remission material of the same patient. Two known SNPs were detected in our patient panel: SNP c.946 C4T (S301S, n ¼ 28, heterozygous) and SNP c.1676 G4A (N545D, n ¼ 2, heterozygous). Six SNPs described in GenBank in the ABCB10 coding region were not present in our patient cohort. colorectal cancers has been performed, 2 leading to the identification of 280 genes as candidate cancer (CAN) genes. Importantly, several of the identified CAN genes are known to be mutated in hematological malignancies, including CBFA2T3 (ETO2), FBXW7, KRAS, NF1, PTEN, RUNX1T1 and TP53.
1,2 Several genes newly identified to be mutated in breast and colorectal cancers belong to the class of ATP-binding cassette (ABC) transporters, 2 which are known to affect the response to therapy of AML and other cancers by conferring chemoresistance. Two of the ABC transporters discovered to harbor novel somatic mutations in breast cancer, the mitochondrial transporters ABCB8 and ABCB10, are highly expressed in both normal and leukemic hematopoietic stem cells.
3 ABCB8 and ABCB10 are structurally closely related and are evolutionary highly conserved, suggesting a fundamental function in cellular physiology. Although their functions have not been completely elucidated, some clues regarding their biological roles can be postulated on the basis of homologues of ABCB10 in other species. Firstly, multi-drug resistance like 1 (MDL1), the ABCB10 homologue from Saccharomyces cerevisiae, regulates cellular responses to oxidative stress, such as reactive oxygen species (ROS). 4 Reactive Oxygen Species signals stimulate proliferation and induce genetic instability in malignant transformed cells, conferring increased basal oxidative stress in cancer cells. 5 ABCB10 might represent an important factor in mediating the response to oxidative stress in cancer cells. Secondly, the murine ABCB10 homologue, ABC-mitochondria erythroid (ABC-me), is a direct target of the transcription factor GATA1 and overexpression of murine ABCB10 enhances hemoglobin synthesis. 6 Furthermore, a recent study identified ABCB10 to be essential for proliferation of human mammary epithelial cells. 7 Thus, mutations in ABCB10 may cause resistance to oxidative stress, thereby contributing to cancer development. In this context, we pursued to investigate whether ABCB8 and ABCB10 are CAN genes in AML. To this end, the coding regions of ABCB8 and ABCB10 were screened by heteroduplex analysis (HA) using genomic DNA isolated from diagnostic bone marrow or peripheral blood samples from a panel of 94 AML patients who were referred to the Department of Hematology at the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, between 1991 and 2004. To identify potential mutations that affect splicing, the first 15 intronic nucleotides surrounding the intron-exon junctions were analyzed as well. Amplicons covering relevant regions were generated by a two-step polymerase chain reaction (PCR) followed by HA (for details see Supplementary Methods and Supplementary Figure S1 and 2; for primer sequences see Supplementary Table S1 ). Fragments exhibiting altered peak patterns in HA were subsequently sequenced to identify the nucleotide changes. Exons with multiple known single nucleotide polymorphisms (SNPs) were subjected to direct sequencing. A limitation of the HA method is that homozygous mutations or SNPs will not be detected. As all reported somatic mutations in ABCB8 and ABCB10 are heterogeneous, 2 we reasoned that most point mutations in the cohort would be detected by HA.
A total of 0.85 Mb of tumor genomic DNA, spanning exons 1-16 of ABCB8 and exons 2-13 of ABCB10, was analyzed (summarized in Supplementary Figure S3) . To ensure that putative mutations were not PCR or sequence artefacts, amplicons containing nucleotide changes were re-amplified and re-sequenced in the corresponding patient samples. This led to the identification of eight new single base substitutions and four described SNPs across the ABCB8 coding region, together with one new single base substitution and two known SNPs in the ABCB10 coding sequences with different frequencies among the studied cohort (Figure 1 and Supplementary Table S2 ). In ABCB8, four of the eight new nucleotide changes predicted amino acid substitutions, distributed in both conserved (transmembrane domain) and non-conserved domains. The remaining four variants did not result in amino acid changes (Figure 1a) . The variant in ABCB10 led to an amino acid substitution in the transmembrane domain as indicated in Figure 1b . The reported polymorphisms (GenBank) in the coding region of ABCB8 include seven non-synonymous and four synonymous SNPs (Figure 1a) , while in the ABCB10 coding sequences five mis-sense and three silent SNPs have been described in GenBank (Figure 1b) . No new changes were observed within 15 base pairs from the exon-intron boundaries (Supplementary Table S2 ). The eight new variants in ABCB8 and the one in ABCB10 were further analyzed to distinguish between somatic mutations and new germ-line variants/polymorphisms. Therefore, the newly discovered nucleotide changes were tested in matched remission samples or in T-cells cultured from cryopreserved peripheral blood from the corresponding patients (see Supplementary Materials and Methods for details). A total of 50 unrelated healthy controls were screened by direct sequencing when remission material was not available to determine whether putative mutations represented novel polymorphisms. Eight out of these nine new variants were present in control samples or T-cells and were hence considered to represent germ-line variants or new polymorphisms (Figure 1) . The remaining putative mutation (c.1572 C4T, G493G), which is located in the coding region of ABCB8, was not further analyzed as it was silent and remission material and cryopreserved material from this case were not available. On the basis of these results we exclude ABCB8 and ABCB10 as cancer genes in AML.
In combination with the known polymorphisms, a total of 19 variants in the ABCB8 coding region and 9 in ABCB10 are present (Figure 1 ). It is reported that functional SNPs and haplotypes in ABC transporter genes may contribute to cancer susceptibility or prognosis. 8 None but one non-synonymous SNP (c.1003 C4T, R304C, ABCB8) detected in our patient cohort had a significantly different frequency (0.123) from that reported (0.339). Therefore, it is interesting to study this finding in independent cohorts of AML patients and controls. The restrained variation in ABCB10 compared with ABCB8 might suggest that the former protein has a more conserved function. Despite the fact that significant overlap has been identified between genes mutated in solid tumors and hematological cancers, 1,2 this study shows that the ABCB8 and ABCB10 genes found to be CAN genes in breast cancer are not mutated in AML. 
